Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection

AIDS

Volumn 18, Issue 15, 2004, Pages 1979-1989

  Alter, Galit ^a   Tsoukas, Christos Micheal ^a   Rouleau, Danielle ^b   Côté, Pierre ^c   Routy, Jean Pierre ^a   Sékaly, Rafik Pierre ^d   Bernard, Nicole Flore ^a,e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Clinique Medicale du Quartier Latin   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

AIDS; Antigen; Cytotoxic T lymphocyte; Epitope; Peptide; Primary infection

Indexed keywords

EFAVIRENZ; GAMMA INTERFERON; INDINAVIR; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONGITUDINAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; PRIMARY INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS IMMUNITY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIBODY FORMATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, MHC CLASS I; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 7744223458     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200410210-00002     Document Type: Article

References (51)

1. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
2. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
3. Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, et al. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci USA 1993, 90:6405-6409.
4. Klein MR, van Baalen CA, Holwerda AM, Kerkhof G, Sr., Bende RJ, Keet IP, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372.
5. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993, 177:249-256.
6. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
7. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998.
8. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334-338.
9. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
10. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001, 193:375-386.
11. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997, 94:1890-1895.
12. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-390.
13. Kaur A, Alexander L, Staprans SI, Denekamp L, Hale CL, McClure HM, et al. Emergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection. Eur J Immunol 2001, 31:3207-3217.
14. O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002, 8:493-499.
15. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997, 94:254-258.
16. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
17. Mellors JW, Kingsley LA, Rinaldo CR, Jr., Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
18. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
19. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999, 179:527-537.
20. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
21. Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, et al. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J Immunol 2001, 171:477-488.
22. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000, 97:3382-3387.
23. Malhotra U, Holte S, Dutta S, Berrey MM, Delpit E, Koelle DM, et al. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001, 107:505-517.
24. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999, 5:512-517.
25. Routy JP, Vanhems P, Rouleau D, Tsoukas C, Lefebvre E, Cote P, et al. Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. J Acquir Immune Defic Syndr 2000, 24:425-432.
26. Alter G, Merchant A, Tsoukas CM, Rouleau D, LeBlanc RP, Cote P, et al. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis 2002, 185:755-765.
27. Cooper DA, Imrie AA, Penny R. Antibody response to human immunodeficiency virus after primary infection. J Infect Dis 1987, 155:1113-1118.
28. Yu K, Daar ES. Primary HIV infection. Current trends in transmission, testing, and treatment. Postgrad Med 2000, 107:114-122.
29. Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001, 134:25-29.
30. Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, Shaw GM, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:305-310.
31. Clark SJ, Shaw GM. The acute retroviral syndrome and the pathogenesis of HIV-1 infection. Semin Immunol 1993, 5:149-155.
32. Quinn TC. Acute primary HIV infection. JAMA 1997, 278:58-62.
33. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998, 280:42-48.
34. McFarland W, Busch MP, Kellogg TA, Rawal BD, Satten GA, Katz MH, et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr 1999, 22:484-489.
35. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995, 46:355-367.
36. Brander C, Korber B, Walker B, Koup R, Moore B, Haynes BF, et al. Recent advances in the optimization of HIV-specific CTL epitopes. In: Molecular Immunology Database. Los Alamos, NM: Los Alamos National Laboratory: Theoretical Biology and Biophysics, 2003.
37. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999, 73:6715-6720.
38. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999, 73:797-800.
39. Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 2001, 75:6508-6516.
40. Soudeyns H, Rebai N, Pantaleo GP, Ciurli C, Boghossian T, Sekaly RP, et al. The T cell receptor V beta repertoire in HIV-1 infection and disease. Semin Immunol 1993, 5:175-185.
41. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994, 370:463-467.
42. Soudeyns H, Campi G, Rizzardi GP, Lenge C, Demarest JF, Tambussi G, et al. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood 2000, 95:1743-1751.
43. Soudeyns H, Champagne P, Holloway CL, et al. Transient T cell receptor beta-chain variable region-specific expansions of CD4+ and CD8+ T cells during the early phase of pediatric human immunodeficiency virus infection: characterization of expanded cell populations by T cell receptor phenotyping. J Infect Dis 2000, 181:107-120.
44. Callan MF, Fazou C, Yang H, Rostron T, Poon K, Hatton C, Silvestri GU, Ringuette N, Samson J, et al. CD8(+) T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest 2000, 106:1251-1261.
45. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
46. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
47. Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996, 70:3098-3107.
48. Kuiken CL, Zwart G, Baan E, Coutinho RA, van den Hoek JA, Goudsmit J. Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci USA 1993, 90:9061-9065.
49. Pang S, Shlesinger Y, Daar ES, Moudgil T, Ho DD, Chen IS. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 1992, 6:453-460.
50. Ferbas J, Daar ES, Grovit-Ferbas K, Lech WJ, Detels R, Giorgi JV, et al. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J Virol 1996, 70:7285-7289.
51. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001, 193:169-180.